[go: up one dir, main page]

ES2124797T3 - Complejos solubles de lactato calcico/acidos quindonacarboxilicos como formas parenterales no irritantes. - Google Patents

Complejos solubles de lactato calcico/acidos quindonacarboxilicos como formas parenterales no irritantes.

Info

Publication number
ES2124797T3
ES2124797T3 ES93923156T ES93923156T ES2124797T3 ES 2124797 T3 ES2124797 T3 ES 2124797T3 ES 93923156 T ES93923156 T ES 93923156T ES 93923156 T ES93923156 T ES 93923156T ES 2124797 T3 ES2124797 T3 ES 2124797T3
Authority
ES
Spain
Prior art keywords
calcium lactate
quindonacarboxylic
irritating
acids
soluble complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93923156T
Other languages
English (en)
Inventor
Surendra C Mehta
Hua-Pin Huang
Galen W Radebaugh
Mahdi B Fawzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2124797T3 publication Critical patent/ES2124797T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE PRESENTAN COMPLEJOS ANTIBACTERIANOS DE LACTATO CALCICO EN FORMAS DE DOSIFICACION PARENTERAL QUE NO IRRITAN PRACTICAMENTE LOS TEJIDOS TRAS SU INYECCION Y QUE CONTIENEN UNA QUINOLONA Y NAFTIRIDINA.
ES93923156T 1992-10-27 1993-09-29 Complejos solubles de lactato calcico/acidos quindonacarboxilicos como formas parenterales no irritantes. Expired - Lifetime ES2124797T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/966,998 US5290794A (en) 1992-10-27 1992-10-27 Soluble calcium lactate antibacterial complexes as non-irritating parenteral forms
PCT/US1993/009252 WO1994009779A1 (en) 1992-10-27 1993-09-29 Soluble calcium lactate/quindonecarboxylic acids on naphthydrinecarboxylic acids complexes as non-irritating parenteral forms

Publications (1)

Publication Number Publication Date
ES2124797T3 true ES2124797T3 (es) 1999-02-16

Family

ID=25512170

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93923156T Expired - Lifetime ES2124797T3 (es) 1992-10-27 1993-09-29 Complejos solubles de lactato calcico/acidos quindonacarboxilicos como formas parenterales no irritantes.

Country Status (13)

Country Link
US (1) US5290794A (es)
EP (1) EP0666743B1 (es)
JP (1) JPH08504190A (es)
AT (1) ATE173925T1 (es)
AU (1) AU670838B2 (es)
CA (1) CA2144652A1 (es)
DE (1) DE69322405T2 (es)
DK (1) DK0666743T3 (es)
ES (1) ES2124797T3 (es)
MX (1) MX9306321A (es)
NZ (1) NZ256962A (es)
SG (1) SG46482A1 (es)
WO (1) WO1994009779A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602254A (en) * 1995-05-26 1997-02-11 Warner-Lambert Company Method for making quinoline carboxylic acids or naphthyridine carboxylic acids in free base form
ID21415A (id) 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
RU2007104026A (ru) * 2004-07-02 2008-08-10 Дайити Фармасьютикал Ко., Лтд. (JP) Содержащая хинолон лекарственная композиция
AU2008276512A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR223983A1 (es) * 1978-08-25 1981-10-15 Dainippon Pharmaceutical Co Un procedimiento para-preparar derivados de acido 6-halogeno-4-oxo-7-(1-piperazinil)-1,8-naftiridin-3-carboxilico
DE3508816A1 (de) * 1985-01-10 1986-07-10 Bayer Ag, 5090 Leverkusen 6,7-disubstituierte 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphtyridin-3-carbonsaeuren
US4771054A (en) * 1985-01-23 1988-09-13 Warner-Lambert Company Antibacterial agents
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
AU594983B2 (en) * 1985-10-29 1990-03-22 Dainippon Pharmaceutical Co. Ltd. Novel quinoline derivatives and processes for preparation thereof
DE3713672A1 (de) * 1987-04-24 1988-11-17 Bayer Ag Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren
US4851418A (en) * 1987-08-21 1989-07-25 Warner-Lambert Company Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent
US4929613A (en) * 1987-08-26 1990-05-29 Warner-Lambert Company Antibacterial agents
DE3831514A1 (de) * 1988-09-16 1990-03-22 Bayer Ag Ph-neutrale waessrige loesungen von chinoloncarbonsaeuren
US5057520A (en) * 1989-03-24 1991-10-15 Abbott Laboratories 7-(peptidylpyrolidinyl)naphthyridine antibacterial compounds
US4916141A (en) * 1989-03-28 1990-04-10 Warner-Lambert Company (S)-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid
NZ232740A (en) * 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
JPH085779B2 (ja) * 1989-09-22 1996-01-24 杏林製薬株式会社 フレロキサシン点眼液
EP0425443A1 (de) * 1989-10-27 1991-05-02 Ciba-Geigy Ag Injizierbares parasitizides Mittel
EP0507851B1 (en) * 1989-12-29 1997-04-02 Abbott Laboratories Quinolone carboxylic acid--metal ion--acid complexes

Also Published As

Publication number Publication date
NZ256962A (en) 1996-08-27
ATE173925T1 (de) 1998-12-15
DK0666743T3 (da) 1999-08-16
SG46482A1 (en) 1998-02-20
AU670838B2 (en) 1996-08-01
CA2144652A1 (en) 1994-05-11
WO1994009779A1 (en) 1994-05-11
DE69322405T2 (de) 1999-04-29
US5290794A (en) 1994-03-01
MX9306321A (es) 1994-04-29
AU5293793A (en) 1994-05-24
EP0666743B1 (en) 1998-12-02
JPH08504190A (ja) 1996-05-07
EP0666743A1 (en) 1995-08-16
DE69322405D1 (de) 1999-01-14

Similar Documents

Publication Publication Date Title
ES2074131T4 (es) Acidos azabicicloquinolonacarboxilicos.
UA41879C2 (uk) Засіб для лікування мотонейронових захворювань
DK0436154T3 (da) Transkutant, implanterbart kateter
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
TR199901127T2 (xx) Antibakteriyel etkili 6-O-ikameli ketolitler.
NO883591D0 (no) Dermal administreringsform.
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
MX9700886A (es) Nuevas oxazolidinonas sustituidas.
MX9203602A (es) Administracion iontoforetica mejorada de farmacos.
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
AU1189688A (en) Utilization of morphine antagonists in the preparation of drugs having an immunomodulator and antiviral effect, particularly for treating acquired immunodeficiency states
DE60030124D1 (de) Hyaluronsäure-ester zur behandlung von normotrophischen hautnarben
ES8500932A1 (es) Procedimiento para la obtencion de acidos quinoloncarboxilicos
PT806941E (pt) Composicoes anti-bacterianas liposomicas de rigidez baixa
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
MY108459A (en) 2-substituted quinolines, processes for their preparation and their use in medicaments
IL96776A (en) Antibacterial compositions containing quinolone carboxylic acid-metal ion-acid complexes
IL91047A (en) Zinc complexes for the treatment of free radical- induced diseases
NO20000446D0 (no) Anvendelse av fysiologisk akseptable vanadiumforbindelser, salter og komplekser
RU93057572A (ru) 6,9-бис(аминозамещенные)-бензо(д)изохинолин-5,10-дионы, способы их получения, фармкомпозиция, способ лечения опухолей
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
ES2124797T3 (es) Complejos solubles de lactato calcico/acidos quindonacarboxilicos como formas parenterales no irritantes.
DE69717988D1 (de) Topische verabreichung von premafloxacin zur behandlung von systemischen bakteriellen erkrankungen
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 666743

Country of ref document: ES